Need professional-grade analysis? Visit stockanalysis.com
$257.95M
3.93
136
N/A
Price Chart
Risk-Adjusted Performance
Also Listed On
Abeona Therapeutics Inc (ABEO) Price Performance
Abeona Therapeutics Inc (ABEO) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $4.45, down 2.20% from the previous close.
Over the past year, ABEO has traded between a low of $4.17 and a high of $7.23. The stock has lost 11.0% over this period. It is currently 38.5% below its 52-week high.
Abeona Therapeutics Inc has a market capitalization of $257.95M, with a price-to-earnings ratio of 3.93.
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $3.50M
- EBITDA
- $-80,984,000
- Profit Margin
- 20587.50%
- EPS (TTM)
- -2.04
- Book Value
- 3.27
Technical Indicators
- 52 Week High
- $7.54
- 52 Week Low
- $3.93
- 50 Day MA
- $5.13
- 200 Day MA
- $5.60
- Beta
- 1.19
Valuation
- Trailing P/E
- 3.93
- Forward P/E
- 526.32
- Price/Sales
- 644.88
- Price/Book
- 1.51
- Enterprise Value
- $292.65M